Zusammenfassung
Sexualhormone werden zur Behandlung von Störungen der Sexualfunktion bei Mann und Frau eingesetzt. Sie dienen in erster Linie zur Substitution einer ungenügenden körpereigenen Hormonproduktion, aber auch zur Hemmung der Hormonproduktion durch Änderung der zentralen Regulationsvorgänge im Zwischenhirn und der Hypophyse. Neben vielen anderen Anwendungen sind Sexualhormone und ihre entsprechenden Antihormone bei der Therapie von Sexualhormonabhängigen Tumoren von Bedeutung.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Arzneimittelkommission der Deutschen Ärzteschaft (2003): Rote Hand Brief zur Hormontherapie im Klimakterium vom 09.12.2003. Im Internet: www.akdae.de/20/40/index.html.
Castelo-Branco C, Vicente JJ, Figueras F, Sanjuan A, Martinez de Osaba MJ, Casals E et al (2000): Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 34: 161–168.
Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR (1995): Estrogen replacement therapy and fractures in older women. Ann Intern Med 122: 9–16.
Cheng L, Gulmezoglu AM, Oel CJ, Piaggio G, Ezcurra E, Look PF (2004): Interventions for emergency contraception.Cochrane Database Syst Rev. 2004; (3): CD001324.
Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, Manson JE, Rodabough RJ, Chien J W, Wactawski-Wende J, Gass M, Kotchen JM, Johnson KC, O‘Sullivan MJ, Ockene JK, Chen C, Hubbell FA; Women‘s Health Initiative Investigators (2009): Oestrogen plus progestin and lung cancer in postmenopausal women (Women‘s Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 374: 1243–1251.
Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F; WHO International Agency for Research on Cancer (2005): Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 6: 552–553.
Collaborative Study Group on the Desogestrel-containing Progesteron-only Pill (1998): A double blind study comparing the contraceptive efficacy, acceptability and safety of two progesteron-only pills containing desogestrel 75 micrograms/ day or levonorgestrel 30 micrograms/day. Eur J Contracept Reprod Health Care 3: 169–178.
Dinger JC, Heinemann LA, Kuhl-Habich D (2007): The safety of a drospirenonecontaining oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75: 344–354.
Fisher B, Constantino J P, Wickerham LD, Redmond CK et al (1998): Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer I 90: 1371–1388.
Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ (2000): A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133: 933–1001.
Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML; WHI Investigators (2008): Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299: 1036–1045.
Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L et al. (2002): Fulvestrant (ICI 182,780) is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing progressing after prior endocrine treatment. J Clin Oncol 20: 3396–3403.
Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R et al. (2004): Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22: 1605–1613.
Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, Eaton CB, Kostis JB, Caralis P, Prentice R; Women‘s Health Initiative Investigators (2006): Conjugated equine estrogens and coronary heart disease: the Women‘s Health Initiative. Arch Intern Med 166: 357–365.
Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E (1998): Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280: 605–613.
Jick H, Jick SS, Gurewich V, Myers M W, Vasilakis C (1995): Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346: 1589–1593.
Kemmeren JM, Algra A, Grobbee DE (2001): Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Brit Med J 323: 1–9.
König HJ (1991): Hirnkreislaufstörungen unter Einnahme gestodenhaltiger hormonaler oraler Kontrazeptiva – Kausalität oder Koinzidenz? Dtsch Ärztebl 91: C-1745– C-1748.
Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; Women‘s Health Initiative Investigators (2003): Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349: 523–534.
Million Women Study Collaborators (2003): Breast cancer and hormone-replacement in the Million Women Study. Lancet 362: 419–427.
Million Women Study Collaborators (2005): Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365: 1543–1551.
Million Women Study Collaborators (2007): Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369: 1703–1710.
Modelska K, Cummings S (2002): Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab. 87:16–23.
NAMS Advisory Panel (2003): Amended report from the NAMS Advisory Panel on postmenopausal hormone therapy.Menopause 10: 6–12.
Nelson HD (2004): Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 291: 1610–1620.
Oddsson K, Leifels-Fischer B, de Melo NR, Wiel-Masson D, Benedetto C, Verhoeven CH, Dieben TO (2005): Efficacy and safety of a contraceptive vaginal ring (Nuva-Ring) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 71: 176–182.
Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R (1995): Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the rennin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 80: 1816–1821.
Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M et al. (2002): A double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant with anastrozole in post-menopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 20: 3386–3395.
Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA (2007): The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356: 1670–1674.
Renoux C, Dell’aniello S, Garbe E, Suissa S (2010): Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 340: c2519.
Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML (2007): Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297: 1465–1477.
Royal College of General Practitioners Oral Contraception Study (1981): Further analysis of mortality in oral contraceptive users. Lancet I: 541–546.
Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F (2004): Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89: 5429–5434.
Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD (1996): Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Brit Med J 312: 83–88.
Tang M-X, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H (1996): Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 348: 429–432.
Van Grootheest K, Vrieling T (2003): Thromboembolism associated with the new contraceptive Yasmin. BMJ 326: 257.
World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995): Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346: 1582–1588.
Womens Health Initiative Steering Committee (2004): Effect of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative randomized controlled trial. JAMA 291: 1701–1712.
Writing Group for the Women’s Health Initiative (2002): Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288: 321–333.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schwabe, U. (2010). Sexualhormone. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2010. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13380-0_42
Download citation
DOI: https://doi.org/10.1007/978-3-642-13380-0_42
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-13379-4
Online ISBN: 978-3-642-13380-0
eBook Packages: Medicine (German Language)